ELIZABETH THOMAS: Open Payments
NPI 1326773771 · WASHINGTON, DC. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$2,220 in 94 payments from 19 companies in 2025. Trend: 2023 $1,575 · 2024 $1,886 · 2025 $2,220
Food & beverage: $2,220
| Company | Payments | Amount |
|---|---|---|
| Janssen Biotech, Inc. | 26 | $607 |
| Ardelyx, Inc. | 12 | $364 |
| ABBVIE INC. | 10 | $223 |
| PFIZER INC. | 10 | $199 |
| Madrigal Pharmaceuticals | 4 | $109 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | 4 | $92 |
| Regeneron Healthcare Solutions, Inc. | 4 | $80 |
| Ipsen Biopharmaceuticals, Inc | 3 | $73 |
| Takeda Pharmaceuticals U.S.A., Inc. | 3 | $66 |
| Lilly USA, LLC | 3 | $65 |
Products named: TREMFYA, IBSRELA, DUPIXENT, CREON, XELJANZ, REZDIFFRA, XIFAXAN, LINZESS.
Industry payments across DC — which companies pay providers there.
